ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance

Journal of Nephrology

Volumn 19, Issue 1, 2006, Pages 91-96

  Saudan, Patrick ^a   Halabi, Georges ^b,t   Perneger, Thomas ^a   Wasserfallen, Jean Blais ^b   Wauters, Jean Pierre ^b   Martin, Pierre Yves ^a   Fellay, G ^c   Descombes, E ^c   Levy, M ^d   Freudiger, H ^e   Brunisholz, M ^f   Robret, D ^g   Giovanini, M ^h   Uldry, P Y ⁱ   Vogel, G ^j   Haldimann, B ^k   Blanc, E ^l   Evequoz, P ^m   Schmid, M ⁿ   Scherrer, P ^o   Wauters, J P ^b,p   Guignard, J P ^b   von Albertini, B ^q   Hudry, M T ^r   Gautier, T ^s   Glueck, Z ^u   more..

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Hopital Cantonal de Fribourg   (Switzerland)

^d LA TOUR HOSPITAL   (Switzerland)

^e Maison de Santé Cité Générations   (Switzerland)

^f Hôpital Porrentruy   (Switzerland)

^g Hopital de la Providence   (Switzerland)

^h Hopital de la Chaux de Fonds   (Switzerland)

ⁱ Hôpital de Martigny   (Switzerland)

^j Hôpital de Monthey   (Switzerland)

^k Unit of Dermatology Hôpital de Sierre   (Switzerland)

^l Hopital de Sion   (Switzerland)

^m Regionalspital Visp   (Switzerland)

ⁿ Regionalspital Brig   (Switzerland)

^o Hôpital de Château d'Oex   (Switzerland)

^p UNIVERSITY OF BERN   (Switzerland)

^q Service de soins intensifs   (Switzerland)

^r Centre de Dialyse de Nyon   (Switzerland)

^s Hopital Riviera   (Switzerland)

^t Hôpital de Zone   (Switzerland)

^u Regionalspital Biel   (Switzerland)

more..

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor blockers; Erythopoietin; Hemodialysis; Renal anemia

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREVALENCE; STATISTICAL SIGNIFICANCE; SWITZERLAND;

AGED; ANEMIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33645469932     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659-64.
2. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-9.
3. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984; 4: 355-60.
4. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991; 17: 199-205.
5. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999; 14: 1836-41.
6. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-44.
7. Griffing GT, Melby JC. Enalapril (MK-421) and the white cell count and haematocrit. Lancet 1982; 1: 1361.
8. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45: 391-9.
9. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of post-transplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26: 495-500.
10. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-10.
11. Erturk S, Nergizoglu G, Ates K, Duman N, Erbay B, Karatan O, Ertug AE. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1912-6.
12. Horl WH, Jacobs C, Macdougall IC, Valderrabano F, Parrondo I, Thompson K, Carveth BC. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 2000; 15 (suppl 4): S43-50.
13. Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. Kidney Int 2001; 60: 1910-6.
14. Conlon PJ, Smith SR, Butterly DW, Brennan DC. Losartan in post-transplant erythrocytosis. Nephrol Dial Transplant 1996; 11: 2524-5.
15. Chew CG, Weise MD, Disney AP. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2047-9.
16. Schiffl H, Lang SM. Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease. Nephron 1999; 81: 106-8.
17. Saudan P, Halabi G, Perneger T, Wasserfallen JB, Kossovsky M, Feldman H, Martin PY, Wauters JP; Western Switzerland Dialysis Study Group. Variability in quality of care among dialysis units in Western Switzerland. Nephrol Dial Transplant 2005; 20: 1854-63.
18. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-13.
19. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609-13.
20. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
21. Hess E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996; 11: 749-51.
22. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 1993; 8: 1428.
23. Matsumura M, Nomura H, Koni I, Mabuchi H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group. Nephron 1997; 77: 164-8.